Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation

• Published in: Journal of experimental & clinical cancer research 2021-03, Vol.40 (1), p.83-83, Article 83
• Main Authors: Zuco, Valentina, Pasquali, Sandro, Tortoreto, Monica, Brich, Silvia, Percio, Stefano, Dagrada, Gian Paolo, Colombo, Chiara, Sanfilippo, Roberta, Lauricella, Calogero, Gounder, Mrinal, El Bezawy, Rihan, Barisella, Marta, Dei Tos, Angelo Paolo, Casali, Paolo Giovanni, Gronchi, Alessandro, Stacchiotti, Silvia, Zaffaroni, Nadia
• Format: Article
• Language: English
• Subjects: Animals; Anthracyclines; Antibiotics, Antineoplastic - pharmacology; Apoptosis; Apoptosis - drug effects; Care and treatment; Cell Dedifferentiation - physiology; Cell Nucleus - metabolism; Chemotherapy; Chromosomal proteins; Cloning; Comparative analysis; Dedifferentiated liposarcoma; Down-Regulation; Doxorubicin; Doxorubicin - pharmacology; Gene amplification; Gene expression; Humans; Hydrazines - pharmacology; International trade; Liposarcoma; Liposarcoma - diagnostic imaging; Liposarcoma - drug therapy; Liposarcoma - metabolism; Liposarcoma - pathology; Male; Metastasis; Mice; Mice, Nude; Patients; PDX; Primary cell culture; Random Allocation; Sarcoma; Selinexor; Software; Survivin - metabolism; Triazoles - pharmacology; Tumor proteins; Tumor Suppressor Protein p53 - metabolism; Tumors; Ubiquitin; Xenograft Model Antitumor Assays; XPO1
• ISSN: 1756-9966; 0392-9078; 1756-9966
• DOI: 10.1186/s13046-021-01886-x

Dedifferentiated liposarcoma (DDLPS), a tumor that lacks effective treatment strategies and is associated with poor outcomes, expresses amplified MDM2 in the presence of wild-type p53. MDM2 ubiquitination of p53 facilitates its XPO1-mediated nuclear export, thus limiting p53 tumor suppressor functions. Consequently, nuclear export is a rational target in DDLPS. We directly compared the antitumor activity of the first-in class XPO1 inhibitor selinexor and doxorubicin, the standard front-line therapy in sarcomas, in DDLPS patient-derived xenografts (PDXs) and primary cell lines. Drug activity was assessed in three PDXs (and two corresponding cell lines) established from the dedifferentiated component of primary untreated retroperitoneal DDLPS with myogenic (N = 2) and rhabdomyoblastic (N = 1) differentiation from patients who underwent surgery. These models were marked by amplification of MDM2, CDK4 and HMGA2 genes. Selinexor was moderately active in the three PDXs but achieved greater tumor response compared to doxorubicin (maximum tumor volume inhibition: 46-80 % vs. 37-60 %). The PDX harboring rhabdomyoblastic dedifferentiation showed the highest sensitivity to both agents. PDX response to selinexor and doxorubicin was not associated with the extent of MDM2 and CDK4 gene amplification. Interestingly, the most chemosensitive PDX model showed the lowest extent of HMGA2 amplification. Selinexor was also more efficient than doxorubicinin in inducing an apoptotic response in PDXs and cell lines. Consistently, an increased nuclear accumulation of p53 was seen in all selinexor-treated models. In addition, a time-dependent decrease of survivin expression, with an almost complete abrogation of the cytoplasmic anti-apoptotic pool of this protein, was observed as a consequence of the decreased acetylation/activation of STAT3 and the increased ubiquitination of nuclear survivin. Selinexor showed a moderate antitumor activity in three DDLPS PDXs, which was, however, consistently higher than doxorubicin across all different models regardless the extent of MDM2 amplification and the histological differentiation. The depletion of survivin protein seems to significantly contribute to the induction of apoptosis through which selinexor exerts its antitumor activity.